APA (7th ed.) Citation

Kansal, K., Babu, B. M., Uppal, G., Liaqat, N., & Dhandapani, A. In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review. Cambridge University Press.

Chicago Style (17th ed.) Citation

Kansal, Khushboo, Betsy Marina Babu, Gaurav Uppal, Nadia Liaqat, and Asha Dhandapani. In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review. Cambridge University Press.

MLA (9th ed.) Citation

Kansal, Khushboo, et al. In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review. Cambridge University Press.